Memed

Memed operates a digital prescription platform in Brazil that links physicians, patients, pharmacies, laboratories, software vendors, pharmaceutical companies and health insurers/operators. Doctors issue prescriptions, exam requests and medical certificates through the platform, drawing on a catalogue of more than 60,000 registered medicines and exam items, including over 3,000 exam items with TUSS and SUS codes, plus reference content on indications, dosages and patient guidance. Prescriptions can be digitally signed using an ICP-Brasil-compliant individual digital certificate (e-CPF) obtained by the physician from a certification authority; signed prescriptions carry signature data as a QR code in the downloadable PDF rather than a signature image. Prescriptions can be sent to patients by WhatsApp or SMS and presented at pharmacies and laboratories without paper.

The platform provides real-time clinical guidance during prescription creation, including drug interaction alerts, dosage recommendations tailored to patient profiles and other clinical decision-support features. For institutional partners it supplies market-intelligence and clinical-intelligence data: pharmaceutical companies use product-performance and market data for sales and marketing digitalization, while hospitals, clinics, laboratories, insurers and health plans use productivity data and real-time monitoring. The company is also developing post-consultation services for doctors to send to patients, such as medication reminders for chronic-disease patients, educational content on drug side effects and dosage guidance.

Memed was acquired in full by healthcare-focused investment firm DNA Capital in 2021 for R$300 million, of which R$100 million was directed to platform expansion; DNA Capital remains the controlling shareholder after the May 2026 round that brought in Bridge One and DGF as new shareholders.

Business model

The platform is free for physicians to use; Memed monetizes through partnerships across the healthcare ecosystem — pharmacies, electronic medical record and software companies, pharmaceutical manufacturers, and hospitals, clinics, laboratories, insurers and health plans — to which it offers integration, digital prescription acceptance, market intelligence, clinical intelligence, productivity data and real-time monitoring.

Physician use of the prescription tool is free of charge; revenue is associated with ecosystem partners (pharmacies, software vendors, pharmaceutical industry, insurers and health operators) that integrate with the platform and consume its data and intelligence offerings.

Traction

Company site figures: more than 262,000 registered physicians, over 2 million patients benefiting annually, 4.7 million prescriptions issued per month, more than 350 partners with 15 integrated health operators, and more than 80,000 pharmacies across Brazil accepting Memed. Press reporting in May 2026 cites around 150,000 doctors using the platform per month and 100 million digital prescriptions generated annually. The company reached breakeven in mid-2025 after 13 years of losses, and headcount grew from 90 to 160 with a plan to end the year at 180.

Latest developments

In May 2026 Memed announced an R$80 million (approximately $14 million) investment round co-led by Bridge One (BridgeOne) and DGF with participation from existing investor DNA Capital, to be used for engineering, product development, data science and hiring technology and product professionals. DNA Capital said it received interest from six funds and chose the two partners for their software-industry expertise, and stated there is no exit date. The company plans to grow from 160 to 180 employees and is developing patient-facing services such as medication reminders and educational content. Management also cited recent ANVISA authorization for digital issuance of controlled prescriptions (Brazil's "yellow" and "blue" prescriptions) as a growth opportunity.